Edition:
United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

4.72USD
26 May 2017
Change (% chg)

$-0.35 (-6.90%)
Prev Close
$5.07
Open
$5.05
Day's High
$5.05
Day's Low
$4.56
Volume
586,404
Avg. Vol
426,117
52-wk High
$6.21
52-wk Low
$1.51

Latest Key Developments (Source: Significant Developments)

ImmunoGen reports positive early-stage data on ovarian cancer drug
Wednesday, 18 May 2016 05:01pm EDT 

Immunogen : Reports efficacy and safety data from a 46 patient cohort of mirvetuximab soravtansine in frα-positive ovarian cancer . Company preparing to meet with FDA in early 3q 2016; targeting initiation of phase 3 study in 4q2016 .Plan to have phase 3 testing of mirvetuximab soravtansine up and running by year end.  Full Article

ImmunoGen Inc Updates FY 2016 guidance
Friday, 29 Apr 2016 06:30am EDT 

ImmunoGen Inc:Updated its guidance for FY 2016.Expected FY 2016 revenues are now projected to be between $60 million and $70 million, compared with previous guidance of between $70 million and $80 million.Guidance for FY 2016 net loss is now expected to be between $135 million and $140 million, compared to its previous estimate of $120 million and $125 million with most of this change being non-cash related.  Full Article

ImmunoGen Inc Appoints Mark J. Enyedy as President and Chief Executive Officer
Tuesday, 26 Apr 2016 08:00am EDT 

ImmunoGen Inc:Mark J. Enyedy has been appointed President and CEO and elected to the Board of Directors, effective May 16.Enyedy succeeds Daniel Junius, who as previously announced is retiring from these positions and will continue to serve on ImmunoGen's Board.  Full Article

ImmunoGen and Merck establish collaboration for clinical evaluation of mirvetuximab soravtansine in combination with keytruda
Thursday, 4 Feb 2016 08:00am EST 

ImmunoGen Inc:Says the company and Merck have entered into a clinical research collaboration for the assessment of ImmunoGen's mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy.Says agreement is between immunogen and Merck, through a subsidiary.Says agreement includes a provision for potential expansion of the collaboration to include a subsequent phase 3 clinical trial.Additional details were not disclosed.  Full Article

ImmunoGen Inc gives FY 2016 guidance
Friday, 31 Jul 2015 06:30am EDT 

ImmunoGen Inc:Says that it expects FY 2016 revenues to be between $70 million and $80 million.Sees FY 2015 net loss to be between $120 million and $125 million.  Full Article

More From Around the Web

ImmunoGen drug moving ahead in single-agent, combination trials

Latest results from a mid-stage trial of ImmunoGen Inc's experimental antibody-drug conjugate show that it shrinks or stabilizes tumors in nearly half of advanced ovarian cancer patients with at least medium levels of a key biomarker whose disease has become resistant to standard chemotherapy.